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Posttranslational  modification  of proteins  often  controls  various  aspects  of  their  cellular  function.  Indeed,
over  the  past  decade  or so,  it has  been  discovered  that  posttranslational  modification  of lysine  residues
plays  a major  role  in regulating  translesion  DNA  synthesis  (TLS)  and  perhaps  the  most  appreciated  lysine
modification  is that  of ubiquitination.  Much  of  the  recent  interest  in  ubiquitination  stems  from  the  fact
that  proliferating  cell  nuclear  antigen  (PCNA)  was  previously  shown  to be specifically  ubiquitinated  at
K164  and  that  such  ubiquitination  plays a key  role  in  regulating  TLS. In addition,  TLS  polymerases  them-
selves  are  now  known  to  be ubiquitinated.  In the  case  of  human  polymerase  , ubiquitination  at  four
lysine  residues  in  its  C-terminus  appears  to regulate  its ability  to interact  with PCNA  and  modulate  TLS.-family polymerase
CNA
Within  the past  few  years,  advances  in  global  proteomic  research  have  revealed  that many  proteins
involved  in  TLS  are,  in  fact, subject  to  a previously  underappreciated  number  of lysine  modifications.  In
this review,  we  will  summarize  the  known  lysine  modifications  of  several  key  proteins  involved  in TLS;
PCNA  and  Y-family  polymerases  ,  ,  and  Rev1  and  we  will  discuss  the  potential  regulatory  effects  of
such  modification  in  controlling  TLS  in  vivo.
©  2015  Published  by  Elsevier  B.V.. Introduction
Posttranslational modifications (PTMs) of proteins by attach-
ng different functional groups to amino acids widens the target
rotein’s range of function and provides additional mechanisms
y which the modified protein can be regulated. For example,
TMs can control a protein’s activity by influencing its ability to
nteract with protein-partners, alter its enzymatic activity, sub-
ellular localization, and change the stability of the protein. Of
ll the experimentally identified PTMs in mammals, serine phos-
horylation is the most frequent modification followed by lysine,
hich represents over 15% of all experimentally identified amino
cid modifications (calculation based on data from [1]). Lysine
an be modified in a variety of ways including, but not limited
o: ubiquitination, ubiquitin-like protein (UBL) modification
Abbreviations: TLS, translesion synthesis; PCNA, proliferating cell nuclear anti-
en;  pol, polymerase; PIP, PCNA-interacting peptide; RIR, Rev1-interacting region;
BM, ubiquitin binding motif; UBZ, ubiquitin binding zinc motif; pol, DNA poly-
erase iota; pol, DNA polymerase eta; pol, DNA polymerase kappa; UBL,
biquitin-like protein; PTM, posttranslational modification; PRR, post replication
NA repair.
∗ Corresponding author. Tel.: +48 22 5921115.
E-mail address: justyna@ibb.waw.pl (J. McIntyre).
ttp://dx.doi.org/10.1016/j.dnarep.2015.02.011
568-7864/© 2015 Published by Elsevier B.V.e.g. SUMOylation, ISGylation, neddylation, FATylation and other
lysine modifications such as acetylation, methylation, butyrylation,
crotonylation, glycation, malonylation, phosphoglycerylation, pro-
pionylation, succinylation, myristoylation [1–4].
Eukaryotic cells have evolved a plethora of mechanisms in order
to protect genome stability by removing DNA lesions, or preventing
their conversion into permanent mutations [5]. Importantly, due
to partially overlapping functions of some of these pathways, or
time and conditional cellular requirements, their actions need to
be precisely controlled. Recent studies in the DNA repair field have
accumulated evidence of an ever expanding role of ubiquitination
in regulating diverse DNA repair mechanisms and pathways
involved in genomic stability maintenance (reviewed in [6]).
Ubiquitin- and ubiquitin-like-dependent signaling processes have
an important function in controlling cellular responses to DNA
damage by navigating through the range of DNA damage repair, or
tolerance mechanisms (reviewed in [6–10]). The majority of DNA
lesions are repaired by one of the specialized DNA repair pathways;
however the repair processes can be slow and incomplete and as a
consequence a number of DNA lesions remain in the template DNA.
This causes a severe problem, especially during the S-phase of the
cell cycle, when DNA is replicated, because efficient and accurate
classical DNA polymerases are blocked at DNA lesions. At this
critical juncture, distinct mechanisms are required to temporarily
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olerate cellular DNA damage, thereby avoiding the permanent
lock to the replication fork and the threat of cell cycle arrest. Lesion
olerance can be achieved in two different ways; one via a damage
voidance pathway using the information from the undamaged
ister chromatid as a template for replication of the damaged
NA region, or via translesion synthesis (TLS), which employs
pecialized DNA polymerases to synthesize past the lesion.
Over the past dozen years, it has become evident that modifica-
ion of lysine residues through the covalent linkage of ubiquitin, or
biquitin-like proteins, plays a central role in controlling both DNA
amage avoidance mechanisms and TLS. This review will attempt
o summarize the known sites and cellular effects of ubiquitin-
tion of several key proteins involved in TLS. We  will recap the
ndividually discovered and experimentally confirmed sites of ubi-
uitination and ubiquitin-like modifications of TLS proteins and
ombine them with recent data derived from multiple proteome-
ide approaches that reveal a hitherto underappreciated extent of
ysine ubiquitination of many of the TLS proteins.
. Types of lysine modifications
.1. Ubiquitination
In eukaryotic cells, ubiquitination is involved in the regulation
f almost all cellular processes, including cell division, membrane
ransport, signal transduction, DNA repair, endocytosis, inflamma-
ory signaling, apoptosis, etc. [11–14]. It has been estimated that
oughly 10% of human genes encode for proteins involved in ubiqui-
in metabolism [15]. The malfunction of ubiquitination processes
nd ubiquitin-mediated proteolysis has been implicated in various
athologies, including neurodegenerative disorders, inflammatory
iseases and cancers [16–19]. Due to their important cellular
unctions, ubiquitination pathways are significant targets for ther-
peutics [20,21].
Protein ubiquitination is a dynamic and reversible process
here a three-step enzymatic cascade conjugates a small, regu-
atory protein, ubiquitin, to a specific lysine residue in a target
rotein [22]. Initially, one of the ubiquitin-activating enzymes (E1s)
orms an ATP-dependent thioester bond with ubiquitin. The acti-
ated ubiquitin is then transferred from the E1 enzyme to one of
ultiple ubiquitin-conjugating enzymes (E2s). E2 then transfers
he activated ubiquitin to a protein substrate, either by itself, or
ith the help of one of the many ubiquitin ligases (E3s). Ubiqui-
in is linked through its C-terminal glycine residue to a specific
nternal lysine residue of the target protein. It has been also shown
hat in some proteins, ubiquitin can be attached to the N-terminus
f the protein and in rare cases to a serine, threonine or cysteine
esidue [23–25]. Monoubiquitinated substrates can undergo fur-
her ubiquitination [26–28]. There are seven lysine residues in
biquitin; K6, K11, K27, K29, K33, K48 and K63; all of them can
e involved in polyubiquitin chain assembly. Additionally linear N-
erminal polyubiquitin chains can also be formed [29]. Depending
n the type of ubiquitin-chain linkage, polyubiquitinated proteins
ight be destined for degradation by the 26S proteasome in an
TP-dependent manner or alternatively, polyubiquitination might
rovide a signal for distinct cellular processes such as the inflam-
atory response or DNA repair [10]. Chains that are linked through
48 are the principal signal for degradation by the proteasome
30,31]. Recent studies, based on mass spectrometry have shown
hat homogeneous chains consisting of K29, K11, K27 and K6-
inkages, heterogeneous chains with mixed lysine linkages, as well
s multiple nearby monoubiquitination and, in cases of substrates
p to 150 amino acids, even monoubiquitination can promote
roteasomal degradation [32,33]. Chain elongation of ubiquitin-
ted substrates is mediated via another class of ubiquitin ligases,epair 29 (2015) 166–179 167
E4s [34,35]. Ubiquitination can be reversed through the activity
of de-ubiquitinating enzymes (DUBs), which primarily disassem-
ble polyubiquitin chains before protein degradation, but will also
cleave off a single ubiquitin moiety, or a polyubiquitin chain to
regulate protein functionality [36].
2.2. Ubiquitin-like posttranslational modification
Besides ubiquitin, at least 10 different ubiquitin-like proteins
(UBLs) exist in mammals (reviewed in [37,38]) with SUMO, NEDD8
and ISG15 being the best known. UBL modifiers, similar to ubiqui-
tin, form an isopeptide bond between their C-terminal glycine and
lysine residues of the substrate [38]. UBLs often have low sequence
homology, but share a similar three-dimensional structure [38].
Posttranslational modification with UBL proteins can alter cellular
function, stability, interactions with protein partners, or subcellu-
lar localization of the target protein [37,39]. Protein modification
by UBLs follows the same three-step cascade similar to ubiquit-
ination in that it is catalyzed by sets of analogous activation (E1),
conjugation (E2s) and ligation (E3s) enzymes and can be reversed
by deconjugating enzymes [40].
SUMO (Small Ubiquitin-like MOdifier) is the most studied UBL
modifier and is expressed in all eukaryotes, mainly as a sin-
gle variant. However in human cells there are four different
paralogs (SUMO1–4), representing various homology, expression
levels and substrate preferences. Many proteins interacting with a
SUMOlyated substrate possess specific SIM domains (from SUMO-
interaction motif) [41]. SUMOylation of a target protein can
influence the protein degradation, signal transduction, localiza-
tion, transcription activation, cell cycle, chromatin organization,
DNA repair and other functions (reviewed in [42]). Dysfunction of
SUMOylation can lead to neurodegenerative diseases, heart defects,
diabetes or cancer [42–45].
One ubiquitin-like molecule, ISG15 (the interferon-stimulated
gene 15), has a primary sequence that consists of two domains
with significant similarity to ubiquitin [46]. Interestingly, ISGyla-
tion shares some of the E2 and E3 enzymes used in ubiquitination
and ISGylated proteins can also be targeted for degradation by the
20S proteasome [47,48]. ISG15 is only found in vertebrates. Type
I interferon, viral infection, lipopolysaccharides and some types
of genotoxic stress can rapidly induce ISG15 conjugation [49,50]
and it has been shown that enhanced ISGylation correlates with
carcinogenesis [51].
Another example, NEDD8 (neural precursor cell-expressed
developmentally downregulated-8), shares 60% identity and 80%
homology with ubiquitin [52], and as a consequence, it can
be incorporated into polyubiquitin chains by the E2 and E3
ubiquitin-conjugating enzymes [53]. The best characterized sub-
strates known to be neddylated are cullins, scaffold proteins of
SCF ubiquitin ligases (Skip-1, cullin, F-box) which regulate ubi-
quitination and proteasomal degradation of proteins involved in
cell cycle control, transcriptional regulation, signal transduction
[37,54]. Other, non-cullin neddylation substrates include proteins
involved in RNA splicing, DNA replication and repair and proteaso-
mal  degradation [55].
3. Identifying ubiquitination and UBL modification sites
The identification of lysine residue(s) to which ubiquitin, or UBL
proteins are conjugated, is important for understanding its bio-
logical significance. Locating ubiquitination, or UBL sites, can be
performed experimentally, using conventional approaches, such
as site-directed mutagenesis of a potentially modified residue
[56,57], or by using antibodies against ubiquitin, or UBL pro-
teins [58,59]. Recently, however, high-throughput methods and
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ass-spectrometry have also been frequently employed [60–67].
 collection of experimentally determined proteins which can
e ubiquitinated and/or UBL-modified proteins in which the
odified residues have been verified have been assembled into sev-
ral searchable databases, such as UbiProt (http://ubiprot.org.ru/)
68], SCUD (http://scud.kaist.ac.kr) [69], for ubiquitin modifica-
ion and SysPTM (http://www.sysbio.ac.cn/SysPTM) [70] and CPLM
http://cplm.biocuckoo.org/index.php) [71] for general PTMs.
.1. Prediction of ubiquitination and UBL sites
The experimental detection of the potential sites of modifica-
ion is time- and labor-intensive, which is why multiple efforts
ave been undertaken to computationally predict protein ubiquit-
nation and UBL sites [72–78]. Generally, they all are based on
nalysing features of experimentally verified ubiquitination sites.
he datasets are used for training via various algorithms and tested
or their prediction ability. Catic and co-workers discovered that
biquitination sites are preferably exposed at the molecular surface
nd reside in loop regions [72]. Kim et al. suggest the ubiquitinat-
on sites localize within a net negative charge [62]. The analysis of
adivojac et al. calculated 586 sequence attributes for each lysine of
he positive and negative datasets and demonstrated that the ubi-
uitination sites are often located in intrinsically disordered regions
74]. This is in contrast to predictions made based on the correlation
f ubiquitination with protein structure performed by Walsh et al.
78] and might be a result of different data sources (Saccharomyces
erevisiae vs. Homo sapiens). These findings generally indicate that
biquitination site preferences seem to be poorly conserved across
ifferent species [61,76,77], therefore organism-specific predictors
hould be used for optimal results.
Several ubiquitin site predictors, such as UbiPred [73], UbPred
74] and CKSAAP UbSite [76], trained on yeast datasets, have been
eveloped. However, quite recently, some predictors have become
vailable exclusively for mammalian sites, such as hCKSAAP UbSite
77], UbiProber [79] and RUBI [78].
For SUMOylation, a consensus motif has been determined as
KxD/E [80] (where  is a hydrophobic residue I, L, M,  P, F, V or
 and X is any residue). However, this motif is not very precise;
bout 40% of known SUMOylation sites do not match the consen-
us, and no detectible SUMOylation was found in some proteins
aving the KxD/E motif [81]. In the last decade, several meth-
ds have been used to generate SUMOylation site predictors, which
nclude GPS, MotifX, SUMOsp, SUMOsp 2.0; seeSUMO, SUMOplot,
UMO-hydro and SUMmOn among others [81–87]. SUMOylation
requently appears to be site-specific, thus prediction programs
ecognize SUMO-modified sites primary on amino acid sequence
nformation.
The high specificity and sensitivity desired in the computational
etermination of ubiquitination and UBL sites remains a challenge.
n a recent paper from Schwartz, that assessed the different avail-
ble predictors, it was pointed out that 9 out of 11 predictors
erform no better than random, or unseen data [88], demonstrat-
ng that at the present time, bioinformatic analysis alone appears
o be insufficient in confidently identifying bona fide sites of ubi-
uitination or SUMOylation. In short, ubiquitin and UBL sites still
eed to be determined experimentally.
.2. Proteome-wide profiling of ubiquitin and UBL modification
The need for the large-scale detection of modified proteins has
een recognized for a long time and within the past several years
he scientific community has witnessed an explosion in the global
dentification of ubiquitinated proteins and sites and to a lesser
xtent, UBL modification [61–67,89–96]. Major progress has been
ade possible due to the development of new affinity purificationepair 29 (2015) 166–179
tools and the improvement of mass spectrometers with increased
speed, resolution and accuracy, together with a decrease in false-
positive recognition [97–99].
The abundance of modified proteins is usually too low to be
directly detected by mass spectrometry, therefore a variety of
methods that enrich modified proteins has been employed. The
strategies for enriching substrates for high-throughput ubiquitin-
ation site recognition include the usage of epitope-tagged ubiquitin
expression system [61,91,94,100,101] and the employment of spe-
cific ubiquitin binding domains and antibodies against ubiquitin
or peptides containing a K--GG remnant that is created by tryptic
digestion of a ubiquitinated protein [93,102–104]. All of the enrich-
ment methods, however, carry some limitations that might lead
to artifacts that one cannot exclude during analysis. For example,
in a system using epitope-tagged ubiquitin, modified proteins can
be purified under denaturing conditions to help reduce false posi-
tive identification. On the other hand, exogenously overexpressed
tagged ubiquitin might hinder the kinetics of ubiquitination reac-
tions, as well as hamper the formation of linear ubiquitin chains
and consequently interfere with the cellular functions of modified
proteins [105,106]. The employment of tandem ubiquitin bind-
ing domains (UBDs) and ubiquitin antibodies circumvents this
problem, but there is an increased risk of co-purifying contami-
nant proteins or a bias toward a specifically modified substrate
(linkage specific polyubiquitinated or monoubiquitinated proteins)
[90,91,107,108]. Both problems are circumvented by using the K-
-GG remnant antibodies developed by Xu et al. [102], as they do
not isolate the entire substrate, but rather a short peptide with the
glycine–glycine signature obtained after tryptic digestion of a ubi-
quitinated substrate. This method is highly efficient and has been
widely used for ubiquitination site profiling [62–65,89,92,109].
It is noteworthy that less abundant ubiquitin-like modifications,
such as neddylation and ISGylation, also generate the same di-
GG signature after trypsinization and the di-GG antibodies do not
discriminate them from ubiquitination [62,110]. The COFRADIC
technology, recently developed by Stes et al. provides an alternative
strategy for ubiquitination studies and does not require overex-
pression, epitope tags or specific antibodies [110].
To date, literally hundreds of mammalian proteins have been
described as SUMOylation targets, however precise identification
of SUMOylated sites remains challenging due to low abun-
dance of modified proteins in vivo and the dynamic character of
SUMOylation [95,111–113]. Several attempts toward large-scale
identification of SUMOylation sites have been undertaken. Most
methods employ recombinant SUMO in in vitro or in vivo SUMOy-
lation assays followed by antibody- or epitope-based purification,
digestion by proteases and mass-spectrometry analysis of the pep-
tide [94–96,112,114–117]. The remnant of SUMO proteins left on
the modified lysine residue after digestion with trypsin is relatively
long (19–32 amino acids depending on the SUMO isoform) leading
to a complex fragmentation pattern which obstructs precise iden-
tification of the SUMOylated site. To overcome this problem and
generate shorter SUMO isopeptide fragments, convenient cleavage
sites were introduced into the SUMO protein allowing for the gen-
eration of a specific di-GG signature after tryptic digestion [66].
84 out of 103 identified SUMO sites were located in direct, or an
inverted SUMO consensus sequences and out of the 16 proteins
that were identified, a new SUMOylation motif HCSM (Hydrophobic
Cluster SUMOylation Motif) was identified.
Additionally, Tammsalu et al. identified over 1000 SUMOy-
lation sites within 539 human proteins involved in cell cycle
regulation, transcription and DNA repair. By using a His-tagged
SUMO2 with a T90K mutation, they obtained a di-GG remnant
after endoproteinase cleavage and the SUMO-enriched peptides
were subsequently analyzed by mass spectrometry [67]. Very
recently, Hendriks et al. identified 4361 SUMOylation sites in 1606
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roteins in human cells, both under normal growth conditions and
n response to heat shock stress, as well as to SUMO protease and
roteasome inhibition [96].
TAP-tagged and GST-tagged Nedd8 were respectively used to
dentify 75 and 496 neddylated proteins by Xirodimas et al. and
ones et al. [55,118]. Various cullin and non-cullin neddylation
ubstrates were discovered including proteins involved in RNA
plicing, DNA replication and repair and proteasomal degradation
55,118].
There are limited reports of large-scale identification of ISGy-
ated proteins. By using high-throughput immunoblotting, for
xample, Malakhov et al. discovered 76 ISG15 substrates involved
n translation, glycolysis, stress response and cell motility [59].
imilarly, by using affinity selection and mass spectrometry Zhao
t al. identified 158 proteins ISGylated in response to interferon
nd functioning in diverse cellular processes [119].
In summary, the wide-assortment of multiple large-scale analy-
es has identified thousands of ubiquitination and UBL modification
ites in numerous proteins. However, the large amount of data
ollected poses a huge challenge to validate the global proteomic
tudies. As discussed above, different strategies raise a variety
f technical and analytical issues, such as contaminant protein
ecognition, pseudo modification, and false-positive assignments.
arious algorithms may  also have different levels of sensitivity and
pecificity that may  bias the data obtained [105]. Therefore, indi-
idual examination and critical evaluation is essential to confirm
lobal modification site profiling.
. Post replication DNA repair (PRR) pathway
DNA damage tolerance pathways allow for temporal acceptance
f the presence of DNA lesions in the genome when there is a risk
f cell death. The most frequent and deleterious are DNA lesions
hat arise during the DNA replication. Very efficient and extremely
aithful polymerases guarantee fast and accurate DNA duplication
uring S-phase. However, any distortion in the DNA structure can
inder this proficient process and cause the replication fork to stall.
f stalled for too long, the replication fork can collapse, generat-
ng DNA double strand breaks that lead to genome instability. It
s therefore critically important to resume replication even in the
ace of persistent DNA damage [120,121]. Based on genetic studies,
RR utilizes two major mechanisms that allow blocked replication
o resume. The first is indirect bypass using DNA damage avoid-
nce mechanism and the second is DNA translesion synthesis (TLS).
he mechanism of DNA damage avoidance is not clear, however it
s thought to involve template switching where the undamaged
ister chromatid is used as a temporary replication template or
omologous recombination [122,123]. In contrast, during TLS, the
ighly precise and efficient DNA replicases that are blocked by a
NA lesion are replaced by specialized, low-processivity TLS poly-
erases that are able to carry out DNA synthesis past the damaged
ite. These TLS DNA polymerases can either bypass the lesion unas-
isted, or with the help of another TLS polymerase in a two-step
rocess [124].
.1. PCNA modifications
It should be noted that in budding yeast, the decision as to which
NA damage tolerance pathway will be undertaken to rescue a
talled replication fork depends on the type of posttranslational
odification to proliferating cell nuclear antigen (PCNA), which is central player in the PRR pathway.
PCNA, a replication processivity factor, is a ring-shaped
omotrimeric complex which encircles double stranded DNA and
lides along the DNA [125]. The monomers, each comprising twoepair 29 (2015) 166–179 169
structurally similar domains, are linked in head-to-tail mode. PCNA
monomers interact with DNA through their DNA binding motifs
(61–80 residues) located on an internal surface. On  the outer sur-
face, the N- and C-terminal halves of PCNA are linked by the
interdomain-connecting loop (IDCL) positioned above a hydropho-
bic pocket that provides a docking site for the PCNA-interacting
peptide (PIP) motif of proteins that interact with PCNA [126]. PCNA
interacts with multiple proteins involved in replication, cell cycle
regulation and DNA repair and coordinates their access to replica-
tion forks (reviewed in [127,128]).
In response to replication fork stalling, PCNA undergoes
monoubiquitination at K164 by Rad6 and Rad18 (E2-ubiquitin con-
jugation and E3-ubiquitin ligase enzyme, respectively) [129,130].
Monoubiquitinated PCNA interacts with TLS polymerases via their
ubiquitin binding domains (UBDs), thereby activating the TLS path-
way. Rad6-Rad18 is the main source of PCNA monoubiquitination,
though some residual, conditional ubiquitination can be observed
in yeast and chicken cells lacking Rad6 or Rad18 [131–133]. There
are also reports that human PCNA can be monoubiquitinated by
CRL4Cdt2 or Rnf8 ubiquitin ligases [134,135]. PCNA ubiquitination
is reversible and modified PCNA can be deubiquitinated via USP1
or BPLF1 (only in human cells) [136–139].
PCNA that is monoubiquitinated at K164 can undergo fur-
ther ubiquitination. In budding yeast, K63-linked polyubiquitin
chains, catalyzed by the Ubc13-Mms2/Rad5 E2-E3 enzymes, pro-
mote template switching [130]. In human cells, there are two Rad5
homologues, HLTF and SHPRH [140–143] serving as the E3 lig-
ases for K63-chain formation. Like yeast Rad5, they both interact
with RAD6/RAD18 and MMS2/UBC13 complexes [140,141], how-
ever, their role is not fully understood and their function in both
damage avoidance and TLS sub-pathways of PRR have been sug-
gested [144]. Furthermore, Krijger et al. suggested the existence of
yet another E3 ligase, as PCNA polyubiquitination was  observed in
HLTF/SHPRH double mutant mice [145]. An additional difference
in PCNA polyubiquitination between lower and higher eukary-
otes regards a requirement for MMS2, as the protein seems to be
dispensable for this process in mammalian cells [146]. PCNA polyu-
biquitination, similar to PCNA monoubiquitination, is negatively
regulated by USP1 [138,141].
Human PCNA is a stable protein with an estimated half-life of
over 20 h. The stability can be attributed to proteins such as MUTH2,
ERK8 and NRAGE, which protect PCNA from polyubiquitination by
blocking proteasome degradation signaling through K48- or K11-
linked chains [147–149].
Yeast PCNA can also be ubiquitinated at K107 in response
to replication stress caused by the presence of unprocessed
Okazaki fragments in ligase-deficient cells. K107 monoubiquitina-
tion signals checkpoint activation and both mono- and K29-linked
polyubiquitination on K107 involves Mms2, Ubc4 and Rad5 [150].
Human PCNA is also ubiquitinated in ligase I depleted cells, but the
modified residue has not yet been identified [150].
In addition to ubiquitination, PCNA can be modified by SUMO.
Initially, this modification was identified in yeast, followed by a
handful of other species including Xenopus and chicken DT40 cells
[129,131,151]. Recently, a low level of SUMOylation of human PCNA
has also been reported [152,153]. SUMOylation is a reversible pro-
cess and Ulp1 hydrolase removes SUMO from PCNA [154].
In budding yeast, PCNA SUMOylation occurs mostly dur-
ing S-phase progression and, by influencing PCNA interactions
with various partners, controls DNA replication and repair. PCNA
SUMOylation promotes the binding of the Srs2 helicase, an inhibitor
of recombination and thereby prevents unwanted recombination
events at the replication fork [155]. Kim et al. showed that the
non-canonical Srs2 PIP box has relatively low affinity for unmo-
dified PCNA but it enhances significantly upon PCNA SUMOylation
[156]. Another interaction involving Elg1, the large subunit of an
1  DNA R
a
S
[
d
P
t
i
[
i
K
E
G
w
r
s
i
h
t
I
[
u
a
t
h
i
o
s
i
a
u
a
I
q
e
d
[
a
a
d
d
l
(
r
e
a
l
f
a
C
K
q
S
u
t
b
I
i
u
p
w70 J. McIntyre, R. Woodgate /
lternative clamp loading complex, implies the involvement of
UMOylation of PCNA in its unloading from DNA in yeast cells
157,158]. Conversely, ATAD5, a human homologue of yeast Elg1,
oes not seem to have a preference for unloading SUMOlyated
CNA despite possessing a SUMO interacting motif [159,160]. On
he other hand, it has been shown to be involved in deubiquitinat-
ng PCNA by recruiting the USP1 complex to ubiquitinated PCNA
155]. PCNA SUMOylation in yeast cells has also been shown to
nhibit Eco1-PCNA-dependent sister chromatid cohesion [161].
Yeast PCNA can be SUMOylated on K164 and to a lesser extent on
127, with the involvement of SUMO conjugating and ligating E2-
3 enzymes, Ubc9 and Siz1 (K164), or just Ubc9 itself (K127) [129].
ali et al. showed that hPCNA can be SUMOylated on K164 and K254
hich prevent DSB formation and inappropriate recombination in
esponse to replication fork arrest by DNA lesions [152]. In another
tudy, the human analog of Srs2, PARI, was shown to promote the
nteraction with SUMOylated PCNA, correspondingly obstructing
omologous recombination [153].
Monoubiquitination of PCNA on K164 strengthens the interac-
ion with TLS polymerases, while yet another lysine modification,
SGylation, promotes release of polymerase  (pol) from PCNA
162]. Upon UV irradiation, either K164 or K168 is assumed to
ndergo ISG15 modification that induces PCNA de-ubiquitination
nd pol discharge followed by PCNA de-ISGylation and resump-
ion of normal replication.
There are 16 lysine residues in human PCNA and 13 of them
ave been reported to be ubiquitinated, either in individual exper-
ments (K164), or by numerous large-scale methods (Fig. 1). Nine
f the identified residues can also be UBL-modified, or acetylated,
uggesting possible competition between different types of mod-
fication. Site-specific overlap between lysine ubiquitination and
cetylation has been suggested for about 20% of identified protein
biquitinations [61] and an interplay between ubiquitination and
cetylation represents a common way to regulate protein stability.
n most cases, lysine acetylation prevents ubiquitination and ubi-
uitin mediated proteolysis of modified protein, but there are some
xamples of acetylation-directed acceleration of protein degra-
ation, by modulating protein–protein interactions (reviewed in
163]). Indeed, Yu et al. showed that UV-induced PCNA acetylation
t K14 caused dissociation of PCNA from a complex with MTH2,
nd as a consequence, shortens its half-life, as PCNA is more easily
egraded by the proteasome [147].
In PCNA, six of the lysines located in the N- and C-terminal
omains were found to be targets of both ubiquitination and acety-
ation. Naryzhny and Lee [164] showed in Chinese hamster ovary
CHO) cells that the PCNA acetylation status plays an important
ole in regulating its function. Indeed, they suggested the exist-
nce of three PCNA isoforms differing in their acetylation status
nd subcellular localization. Additionally, they implied that acety-
ated PCNA is involved in DNA replication, while its deacetylated
orm with replication termination, as acetylated PCNA has higher
ffinity for pol and pol, compared to the deacetylated form.
UBL modifications were identified at four lysine residues in the
-terminal half of the protein. The most modified lysine residue is
164, as all of the global ubiquitin profiling studies detected ubi-
uitination at this site. Additionally, K164 can also be a subject of
UMOylation, ISGylation and acetylation. The structural studies of
biquitinated PCNA suggest that the ubiquitin moieties attached
o K164 of PCNA monomers extend away from the ring and do not
lock the interactions of PIP box containing proteins with PCNA.
t seems, however, that the type of modification can control the
nteracting partner by strengthening the interaction between the
biquitin, or UBL, on PCNA and UBD, or UBL binding motif on the
rotein [165].
Two of the identified lysine residues, K77 and K80, are placed
ithin the DNA binding domain, implying possible obstruction ofepair 29 (2015) 166–179
DNA–PCNA binding upon modifications at any of these sites. Two
other lysines, K110 and K117, in which ubiquitination was detected
in multiple studies, lie within a segment of 101–120 amino acids
found to play an essential role for PCNA nuclear location [166]. Even
though both K110A and K117A mutants are efficiently imported to
the nucleus, K110A does not co-localize with replication foci sug-
gesting that ubiquitination of this residue might influence PCNA
foci formation.
4.2. Modifications of Y-family polymerases
While it is apparent that many of the recently characterized DNA
polymerases have the ability to facilitate TLS of certain DNA lesions,
the best characterized from an historical perspective are the four
Y-family DNA polymerases pol, pol,  pol, and Rev1 and the B-
family DNA polymerase, pol	 [167,168]. Each of these polymerases
presents a specific portfolio of DNA lesions they are able to bypass
with differing efficiency and accuracy. The Y-family polymerases
are multi-domain proteins. The catalytic domain generally occupies
the N-terminus, while the C-terminus is engaged in protein-protein
interactions and contains various protein-binding motifs. Poly-
merases ,  and  possess non-canonical PCNA-binding motifs (PIP
box) and a Rev1 interacting region (RIR) [168]. Rev1 interacts with
PCNA via a BRCT domain localized at its extreme N-terminus while
the C-terminus of Rev1 interacts with polymerases ,  and . All
Y-family DNA polymerases have ubiquitin binding domains that
bind non-covalently to ubiquitin, or ubiquitinated proteins. Poly-
merases  and Rev1 possess two  UBMs, while polymerases  and
, have so called UBZs – UBDs that additionally bind a zinc atom
(pol has one UBZ, whereas pol has two  UBZs) [168–170]. Besides
possessing UBDs that facilitate the interaction with monoubiqui-
tinated PCNA, human pol, pol, mouse pol and Rev1 as well as
yeast and nematode pol have been shown to be subject to ubiquit-
ination themselves [169,171–177]. In general, most of the proteins
that can non-covalently bind ubiquitin via different types of UBDs
are themselves targets of monoubiquitination in a process called
coupled monoubiquitination [178,179]. In this process, ubiquitin
attached to an E2 ubiquitin conjugating enzyme, or E3 ubiquitin
ligase, is recruited to the UBD containing substrate which becomes
ubiquitinated in an E3-dependent, or independent mode [180].
4.2.1. DNA polymerase  modifications
Pol is possibly the best-characterized Y-family DNA poly-
merase and is mainly known for efficient replication past
cyclobutane pyrimidine dimers, which are the main DNA  lesions
induced after UV-irradiation. As a consequence, a dysfunction in
human pol results in the variant form of Xeroderma Pigmen-
tosum, which is characterized by sunlight sensitivity and a high
incidence of skin cancer [182,183].
It has previously been shown that human pol can be ubiquit-
inated in vivo in its nuclear localization signal (NLS) motif. K682
was identified as the main ubiquitination site, however when this
residue is unavailable, three other close by lysines (K686, K694
or K709) can serve as a target [169,171]. Pirh2, an E3 ligase, was
discovered to interact with human pol and monoubiquitinate
it at one of the four lysine residues at the C-terminus [184,185].
Attaching a ubiquitin moiety to the C-terminus of pol prevents
its interaction with PCNA and inhibits its ability to bypass UV-
induced lesions and causes an increased sensitivity to UV radiation
[171,185]. Therefore, monoubiquitinated pol needs to be actively
de-ubiquitinated prior to interacting with PCNA and its recruit-
ment to a stalled replication fork [171]. Additionally, pol is a
subject of polyubiquitination by another E3 ligase, Mdm2, that
targets pol for proteasomal degradation and controls its sta-
bility in response to UV-induced DNA damage [186]. Wallace
et al. showed that human pol can also be polyubiquitinated
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Fig. 1. Posttranslational modification of human PCNA. Lysines that have been indicated to be ubiquitinated are shown with a colored circle. Lysines that have been indicated
to  be acetylated are shown with a colored square. Lysines that have been indicated to be SUMOylated are shown by a colored triangle. The lysine residue that is ISGylated is
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y a RING E3 ligase, TRIP (TRAF-interacting protein) (tumor
ecrosis factor receptor (TNFR)-associated factor) and TRIP pro-
otes its localization in nuclear foci [187]. The TRIP homolog in
rosophila melanogaster, NOPO, enhances ubiquitination of pol
uring insect embryogenesis [187]. Most probably NOPO promotes
on-proteolytic polyubiquitination, as its overexpression does not
ause pol destabilization and additionally, NOPO interacts with
endless (Ben), the Drosophila homolog of Ubc13, suggesting the
ormation of K63-linked polyubiquitin chains [188].
Recently, the deubiquitinating enzyme, USP7, has been reported
o regulate the stability of human pol in two ways. On one hand,
SP7 can directly deubiquitinate pol which stabilizes pol, and on
he other hand, knockout of USP7 increases the steady-state level
f pol by destabilizing Mdm2  [189].
S. cerevisiae pol was also found to be ubiquitinated
173,175,176]. However, the particular ubiquitination sites were
ot identified. Nevertheless, it has been shown that similar to
uman pol,  the ubiquitination depends on a functional UBZ
omain [169,175]. Ubiquitination of yeast pol is correlated with
he cell cycle and increases during G1 and drops as cells enter
-phase, thereby allowing for the recruitment of pol to PCNA
hat is monoubiquitinated in response to a replication block [173].
here are contradicting reports about the stability of yeast pol
172,173] because it appears that the half-life of the yeast enzymereen star. References are given in the appropriate associated box.
largely depends on the epitope tag used to identify the recombinant
enzyme [190,this issue].
Interestingly, in response to DNA damaging agents (MMS and
UV), nematode pol becomes SUMOylated by GEI-17 SUMO E3
ligase at K85 and K260 and protects it from degradation mediated
by CRL4-CDT-2-dependent ubiquitination [174,181]. The SUMOy-
lated lysine residues are conserved in human pol (K86 and K261
respectively), and very recently human pol has been reported
to be SUMOylated at K163 (Patricia Kannouche and Emmanuelle
Despras, personal communication).
In addition to ubiquitination and SUMOylation, human pol can
also be phosphorylated by both ATR kinase and protein kinase C
(PKC), in response to UV radiation. Potential phosphorylation sites
were reported at S587, T617 and S601 by two  independent groups
[191,192]. The phosphorylation of pol seems to be required for
cell survival after UV radiation and provides a link between DNA
damage-induced checkpoint control and translesion synthesis.
There are 47 lysine residues in human pol. In 7 out of 13
large-scale studies, pol was  found to be ubiquitinated (Fig. 2). In
total, the ubiquitination of 14 lysine residues was reported, but
10 of them were identified in single analysis implying that they
might represent non-specific modifications. All 7 global approaches
that showed pol ubiquitination identified K682, thereby indepen-
dently confirming the primary ubiquitination site originally found
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y Bienko et al. [171]. Three neighboring lysine residues, K686,
694 and K709 were also identified as back-up sites of ubiquit-
nation, again, as previously reported by Bienko et al. [171].
.2.2. DNA polymerase  modifications
DNA pol is a paralog of pol [193] and is thought to bypass a
umber of lesions in vivo especially when pol is absent (e.g. in
PV cells) and due to its reduced accuracy in synthesizing across
hotoproducts, pol-dependent TLS results in elevated mutagen-
sis [194–198]. Extensive biochemical studies performed in vitro
ith the highly purified enzyme suggest that pol is able to bypass a
ide range of DNA lesions [199–202]. Interestingly, when copying
n undamaged template, its accuracy varies 10,000-fold depend-
ng on the template base copied (reviewed in [203]). Its unusual
reference of incorporating G opposite T (3–10-fold greater than
he correct base, A) gives pol a distinctive signature [204,205]
nd is a result of the specific structure of its active site [206,207].
nother interesting feature of pol is that its N-terminus con-
ains two partially overlapping catalytic domains; one with DNA
olymerase activity and one with dRP lyase activity [208,209].
he C-terminus contains motifs characteristic of other Y-family
olymerases and includes PCNA-interacting (PIP), Rev1-interacting
RIR) and ubiquitin-interacting (UBM1 and UBM2) motifs/domains.
To date, the only reported posttranslational modification in
uman pol is ubiquitination [169] and the cellular function of
biquitinated pol is not fully understood. However, our previous
tudies implied that ubiquitination of either pol or pol is required
or the two polymerases to physically interact [210].
There are 53 lysine residues in human pol. In 8 total large-scale
tudies, 24 lysine residues distributed along the entire length of the
olymerase were found to be ubiquitinated (Fig. 3). Ubiquitinationed to be ubiquitinated are shown with a colored circle. The serine residues that are
propriate associated box.
of half of these residues was  detected just once, suggesting that
the modifications might have appeared either accidentally, or
represent rather rare conditional cases. The remaining 12 modi-
fied lysines were found to be ubiquitinated in 2–4 independent
approaches, often using different experimental strategies. We
believe that multiple autonomous detection of the same residue
thereby increases the probability that the ubiquitination of any
particular lysine has a functional meaning and possibly a broader
cellular effect. Nonetheless, no single lysine has appeared in all of
the analyzed studies.
Thirteen of the detected ubiquitination sites are located in the
polymerase catalytic domain and the proposed dRP lyase domain,
suggesting that ubiquitination of some of these lysines could pos-
sibly influence the enzymatic activities of pol.  Ubiquitination of
K309 was  detected in four independent approaches and nearby
K310 in two, giving these residues a higher possibility of bona
fide modification. Ubiquitination targets were also reported in two
adjacent lysines, K549 and K550, of the RIR motif suggesting con-
trol of the Rev1–pol interaction. The detection of ubiquitination
of both lysines suggests that either one could serve as a modifica-
tion target. Several other ubiquitination sites were detected at, or
in close proximity to the UBM motifs, which could possibly affect
the ability of pol to bind to ubiquitinated proteins (such as PCNA
or pol).
4.2.3. DNA polymerase  modifications
Pol is able to bypass multiple types of DNA lesions includ-ing abasic sites and bulky adducts, but with rather low efficiency
[211] and due to a constricted active site, cannot incorporate a
base opposite a pyrimidine dimer [212]. When copying an undam-
aged template, pol is quite accurate compared to other Y-family
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olymerases, but can also extend mispaired primer termini [213].
urthermore, after UV-irradiation the activity of pol has been
mplicated in the gap-filling step of nucleotide excision repair [214].
Similar to other Y-family DNA polymerases, pol possesses a
atalytic domain at its N-terminus while the C-terminal half of the
rotein contains domains involved in protein–protein interactions
ncluding an RIR, two UBZ domains and at the extreme C-terminus,
 PIP box [215,216]. The UBZ domains mediate the enhanced inter-
ction with PCNA and some studies report that they are essential
or UV-induced nuclear foci formation by pol,  but do not affect
rotein’s half-life [177]. On the other hand, Okada et al. suggests
hat pol can function independently of PCNA modification [216].
ecent studies of Wit  et al. concluded that dependent on the type
f DNA damage, PCNA ubiquitination may, or may  not, be required
or pol activation [217].
To date, several reports show evidence for posttranslational
odifications to pol in eukaryotic cells. Guo et al. observed
onoubiquitination of mouse pol and confirmed that similar to
ther Y-family polymerases, monoubiquitination depends on UBDs
177]. Endogenously expressed murine pol is a stable protein with
 half-life estimated to be ∼5.4 h [177]. The turnover of exogenously
xpressed pol is somewhat faster (3.7–4.2 h), but does not change
n pol UBZ mutants. The suggestion that human pol might also
e ubiquitinated comes from the publication of Wallace et al. which
eports an interaction between the C-terminus of pol and the RING
3 ligase, TRIP [187]. On the other hand, the possibility of pol E3-
ndependent monoubiquitination has also been reported in vitrod to be ubiquitinated are shown with a colored circle and the appropriate reference
[179]. The biological function of pol modification is not yet known.
However, by influencing pol interactions with other proteins, it
may  regulate its presence in replication factories.
Regarding other types pol modification, Roerink et al. sug-
gested that GEI-17, which is known to SUMOylate and consequently
protect nematode pol from proteasomal degradation, most likely
also acts on pol [181], so it is entirely possible that pol may also
be SUMOylated in vivo.
Until now, the information about which lysine residues can be
modified in pol comes from large-scale proteomics analysis. There
are 84 lysine residues in human pol.  Just four of the over 13 inde-
pendent global studies have reported ubiquitination of pol at 36
lysines (Fig. 4). It should be noted that most of these sites were
detected in just one single analysis. Only K173, K461 and K541
were detected in two  studies and K683 in three studies. Indeed,
the majority of pol expressed in vivo is not ubiquitinated [177],
which probably explains the limited number of studies reporting
ubiquitination of pol. In a recent publication on proteome wide
SUMOylation, Hendriks et al. [96] reported SUMO2 modifications at
six pol lysine residues; half of which, K55, K224 and K814 overlap
with known ubiquitination sites.
4.2.4. Rev1 modifications
Rev1 is a unique enzyme among Y-family polymerases, as it is
only able to incorporate dCMP nucleotides opposite undamaged
or damaged template G and some DNA lesions, including an aba-
sic site [218–221]. Besides its distinctive enzymatic activity, Rev1
174 J. McIntyre, R. Woodgate / DNA Repair 29 (2015) 166–179
Fig. 4. Posttranslational modification of human DNA pol. Lysines that have been indicated to be ubiquitinated are shown with a colored circle. Lysines that have been
indicated to be SUMOylated are shown by a colored triangle. The appropriate references are cited in the associated box.
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wlso plays a non-catalytic role in TLS as a scaffolding protein that
oordinates the other TLS polymerases. The extreme C-terminus of
ev1 in higher eukaryotes is devoted to the interaction with pols
, ,  and 	 [222–227]. Additionally the two UBMs that are located
lose to the C-terminal domain permit the interaction with ubiqui-
in, ubiquitinated PCNA, or other ubiquitinated proteins [170,228].
nterestingly, Rev1 lacks a well-conserved PIP box, that is charac-
eristic of the other Y-family polymerases and the interaction with
CNA is, instead, through the N-terminal BRCT domain of Rev1
229,230].
In addition to non-covalent interacts with ubiquitin and ubiquit-
nated proteins, at least two studies have shown that mouse and
uman Rev1 can also be directly conjugated to ubiquitin [176,231].
owever, the mechanism and sites of the ubiquitination remain
nknown. Kim et al. reported that ubiquitinated human Rev1 can
e recruited to nuclear foci by the Fanconi Anemia core complex,
s it binds directly to the UBZ4 domain of FAAP20 protein [231].
oreover, the level of S. cerevisiae Rev1 seems to be regulated
n a cell cycle-dependent mechanism via ubiquitin-mediated pro-
easomal degradation, suggesting that it gets ubiquitinated before
egradation [232].
There are 92 lysine residues in human Rev1. However, ubiquitin-
tion of Rev1 was detected in just one of the large-scale proteomic
tudies [64]. Out of 7 lysine modifications 5 localize to the N-
erminus (K28, K41, K119, K134 and K140), which are located near,
r within, the BRCT domain. The remaining ubiquitinated lysines
ere located in the middle of the protein (K678 and K770).SUMO2 modification of human Rev1 at K99 has also been
reported [96]. In another proteome-wide analysis, Drosophila
melanogaster Rev1 was shown to be acetylated at K136 [233]. How-
ever, in human Rev1, this residue is replaced by arginine (R149).
These results suggest that Rev1 modifications (most probably at
the N-terminus), occurs either rarely, or under highly specific con-
ditions not employed in the global proteomic studies.
5. Concluding remarks
Review of the published data reveals interesting differences in
the extent of posttranslational modification of key TLS proteins.
PCNA is the most highly modified protein and is subject to ubi-
quitination, acetylation, SUMOylation, ISGylation and neddylation.
Human pol is a target of limited ubiquitination, primarily at one
key residue, K682, and is also been reported to undergo phosphor-
ylation and very recently SUMOylation. In contrast, nearly 50% of
the lysines in pol can apparently be ubiquitinated. This is also in
dramatic contrast to either the pol or Rev1 proteins, which appear
to undergo limited lysine (or any other) posttranslational modifi-
cation. It will therefore be interesting to determine why  pol is so
highly ubiquitinated and the effects such ubiquitination have on
the regulation and in vivo properties of the enigmatic pol enzyme.Conflict of interest
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